Table 4.

Best response in patients with anaplastic large-cell lymphoma, inflammatory myofibroblastic tumour, or non-small-cell lung cancer, by accession number

	Dose level (mg/m² per dose)	Part	Measurable or evaluable disease	Best response	Cycle maximum response observed	Total cycles
Anaplastic large-cell lymphoma (n=9)
Patient 37	165	A2	Measurable	SD	..	>30^*
Patient 38	165	A2	Measurable	CR	2	9^†
Patient 39	165	A2	Measurable	CR	1	>28^*
Patient 41	165	A2	Measurable	CR	5	6^†
Patient 42	165	A2	Measurable	CR	3	>23^*
Patient 43	165	A2	Measurable	CR	1	4^†
Patient 57	280	A2	Measurable	CR	2	12
Patient 62	280	A2	Evaluable	CR	2	>16^*
Patient 78	280	A2	Measurable	PR	1	>7^*

Inflammatory myofibroblastic tumour (n=7)
Patient 4	100	A1	Measurable	SD	..	24
Patient 45	165	A2	Measurable	PR	1	>20^*
Patient 48	280	A1	Measurable	PR	5	>19^*
Patient 69	280	A2	Measurable	SD	..	>14^*
Patient 73	280	A2	Evaluable	SD	..	5
Patient 74	280	A2	Measurable	SD	..	3
Patient 75	280	A2	Measurable	PR	3	>11^*

Non-small-cell lung cancer (n=2)
Patient 30	165	A2	Measurable	SD	..	5
Patient 36	165	A2	Measurable	PR	3	16

SD=stable disease. CR=complete response. PR=partial response.

Patient still on protocol therapy.

^†

Patient off treatment to receive bone marrow transplant.